Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the UK-US Pharmaceutical Trade Deal on the Scottish Medicines Consortium's assessments of the cost effectiveness of new medicines.

The changes to the National Institute for Health and Care Excellence cost-effectiveness threshold and value set which were agreed in the United Kingdom and United States’ pharmaceuticals arrangement do not apply in Scotland, and there is no direct impact on the work of the Scottish Medicines Consortium.